On March 28, 2019 Seattle Genetics, Inc. (Nasdaq:SGEN) reportd that it will host a conference call and webcast discussion regarding the positive topline results from its pivotal clinical trial of enfortumab vedotin in locally advanced or metastatic urothelial cancer, which were announced in a press release earlier today (Press release, Seattle Genetics, MAR 28, 2019, http://investor.seattlegenetics.com/news-releases/news-release-details/seattle-genetics-host-conference-call-positive-topline-results [SID1234534713]). Access to the event can be obtained as follows:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
LIVE access on Thursday, March 28, 2019
6:00 a.m. Pacific Time (PT) / 9:00 a.m. Eastern Time (ET)
Telephone 866-288-0540 (domestic) or +1 786-460-7199 (international); conference ID 3807860
Webcast available at www.seattlegenetics.com in the Investors section
REPLAY access
Telephone replay will be available until 5:00 p.m. PT on Monday, April 1, 2019 by calling 888-203-1112 (domestic) or +1 719-457-0820 (international); conference ID 3807860
Webcast replay will be available on the Seattle Genetics website at www.seattlegenetics.com in the Investors section